Sotagliflozin Reduces HF Events in T2DM Regardless of Baseline Characteristics, Including HF, CKD and LVEF
Saved in:
Published in | Cardiovascular drugs and therapy Vol. 35; no. 5; pp. 1077 - 1078 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
New York
Springer US
01.10.2021
Springer Nature B.V |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Bibliography: | SourceType-Other Sources-1 ObjectType-Article-2 content type line 63 ObjectType-Feature-1 ObjectType-Correspondence-3 |
---|---|
ISSN: | 0920-3206 1573-7241 |
DOI: | 10.1007/s10557-021-07203-0 |